Verve TherapeuticsVERV Market cap $423M
About: Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
Employees: 255
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
41% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 46
1% more funds holding
Funds holding: 162 [Q1] → 164 (+2) [Q2]
6% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 32
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
8.03% less ownership
Funds ownership: 98.67% [Q1] → 90.64% (-8.03%) [Q2]
43% less call options, than puts
Call options by funds: $576K | Put options by funds: $1M
66% less capital invested
Capital invested by funds: $1.1B [Q1] → $372M (-$724M) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Canaccord Genuity Whitney Ijem 37% 1-year accuracy 10 / 27 met price target | 480%upside $29 | Buy Maintained | 12 Aug 2024 |
HC Wainwright & Co. Mitchell Kapoor 43% 1-year accuracy 20 / 46 met price target | 200%upside $15 | Buy Reiterated | 12 Aug 2024 |
RBC Capital Luca Issi 25% 1-year accuracy 13 / 53 met price target | 300%upside $20 | Outperform Maintained | 9 Aug 2024 |
Financial journalist opinion
Based on 245 articles about VERV published over the past 30 days